- Home
- MGRX vs SHPH Comparison
MGRX vs SHPH Comparison
Compare MGRX & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- SHPH
- Stock Information
- Founded
- MGRX 2021
- SHPH 2012
- Country
- MGRX United States
- SHPH United States
- Employees
- MGRX N/A
- SHPH N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- SHPH Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- SHPH Health Care
- Exchange
- MGRX Nasdaq
- SHPH Nasdaq
- Market Cap
- MGRX 8.1M
- SHPH 2.3M
- IPO Year
- MGRX 2023
- SHPH 2022
- Fundamental
- Price
- MGRX $1.52
- SHPH $3.97
- Analyst Decision
- MGRX
- SHPH
- Analyst Count
- MGRX 0
- SHPH 0
- Target Price
- MGRX N/A
- SHPH N/A
- AVG Volume (30 Days)
- MGRX 172.2K
- SHPH 220.3K
- Earning Date
- MGRX 08-13-2025
- SHPH 05-08-2025
- Dividend Yield
- MGRX N/A
- SHPH N/A
- EPS Growth
- MGRX N/A
- SHPH N/A
- EPS
- MGRX N/A
- SHPH N/A
- Revenue
- MGRX $511,084.00
- SHPH N/A
- Revenue This Year
- MGRX N/A
- SHPH N/A
- Revenue Next Year
- MGRX N/A
- SHPH N/A
- P/E Ratio
- MGRX N/A
- SHPH N/A
- Revenue Growth
- MGRX N/A
- SHPH N/A
- 52 Week Low
- MGRX $1.32
- SHPH $3.00
- 52 Week High
- MGRX $7.66
- SHPH $107.40
- Technical
- Relative Strength Index (RSI)
- MGRX 36.15
- SHPH 46.06
- Support Level
- MGRX $1.46
- SHPH $3.29
- Resistance Level
- MGRX $2.04
- SHPH $4.60
- Average True Range (ATR)
- MGRX 0.18
- SHPH 0.49
- MACD
- MGRX -0.06
- SHPH 0.14
- Stochastic Oscillator
- MGRX 8.96
- SHPH 60.66
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.